CN1124133C - 橙皮苷和橙皮素作为肝病的预防或治疗剂的应用 - Google Patents
橙皮苷和橙皮素作为肝病的预防或治疗剂的应用 Download PDFInfo
- Publication number
- CN1124133C CN1124133C CN98810701A CN98810701A CN1124133C CN 1124133 C CN1124133 C CN 1124133C CN 98810701 A CN98810701 A CN 98810701A CN 98810701 A CN98810701 A CN 98810701A CN 1124133 C CN1124133 C CN 1124133C
- Authority
- CN
- China
- Prior art keywords
- hesperidin
- hesperetin
- cholesterol
- inhibitor
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 title claims abstract description 147
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 title claims abstract description 91
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 title claims abstract description 87
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 title claims abstract description 84
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 title claims abstract description 84
- 229940025878 hesperidin Drugs 0.000 title claims abstract description 84
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 title claims abstract description 84
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 title claims abstract description 84
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 title claims abstract description 69
- 229960001587 hesperetin Drugs 0.000 title claims abstract description 63
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 235000010209 hesperetin Nutrition 0.000 title claims abstract description 63
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 238000009825 accumulation Methods 0.000 title abstract description 11
- 125000002252 acyl group Chemical group 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title description 7
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims abstract description 10
- 230000003405 preventing effect Effects 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 26
- 235000013305 food Nutrition 0.000 claims description 15
- 235000015067 sauces Nutrition 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 235000014347 soups Nutrition 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 6
- 208000010706 fatty liver disease Diseases 0.000 claims description 6
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 5
- 240000003768 Solanum lycopersicum Species 0.000 claims description 5
- 235000014510 cooky Nutrition 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 235000015203 fruit juice Nutrition 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 235000015192 vegetable juice Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 3
- 235000008429 bread Nutrition 0.000 claims description 3
- 235000012495 crackers Nutrition 0.000 claims description 3
- 235000012149 noodles Nutrition 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 235000013550 pizza Nutrition 0.000 claims description 2
- 235000011888 snacks Nutrition 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims 3
- 244000269722 Thea sinensis Species 0.000 claims 1
- 235000013616 tea Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 208000019423 liver disease Diseases 0.000 abstract description 15
- 210000003038 endothelium Anatomy 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 91
- 235000012000 cholesterol Nutrition 0.000 description 40
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 11
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- 230000002265 prevention Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 8
- 229960004844 lovastatin Drugs 0.000 description 8
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 241000053227 Themus Species 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001589 microsome Anatomy 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 240000004307 Citrus medica Species 0.000 description 3
- 241001672694 Citrus reticulata Species 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000000497 foam cell Anatomy 0.000 description 3
- 235000013882 gravy Nutrition 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 101800002326 Adipokinetic hormone Proteins 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 235000009392 Vitis Nutrition 0.000 description 2
- 241000219095 Vitis Species 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- -1 as carrier Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000021444 pepsi cola Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- YUMHJXLSSASJGN-ZYHUDNBSSA-N (-)-Acaterin Natural products CCCCCCC[C@@H](O)C1=C[C@@H](C)OC1=O YUMHJXLSSASJGN-ZYHUDNBSSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- YUMHJXLSSASJGN-UHFFFAOYSA-N 4-(1-hydroxyoctyl)-2-methyl-2h-furan-5-one Chemical compound CCCCCCCC(O)C1=CC(C)OC1=O YUMHJXLSSASJGN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- 239000003818 cinder Substances 0.000 description 1
- 235000021443 coca cola Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- XDUHQPOXLUAVEE-BPMMELMSSA-N oleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XDUHQPOXLUAVEE-BPMMELMSSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013997 pineapple juice Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229930188995 pyripyropene Natural products 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Seasonings (AREA)
- Dairy Products (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
Abstract
本发明涉及橙皮苷和橙皮素在哺乳动物中抑制酰基CoA-胆固醇-O-酰基转移酶(ACAT)的活性、抑制巨噬细胞-脂质复合物在动脉壁上的累积、以及预防或治疗肝病的应用。
Description
发明领域
本发明涉及橙皮苷和橙皮素在哺乳动物中抑制酰基CoA-胆固醇-O-酰基转移酶(ACAT)的活性、抑制巨噬细胞-脂质复合物在动脉壁上的累积、以及预防或治疗肝病的应用。
发明背景
近些年来,冠状心血管循环疾病,例如动脉粥样硬化和高胆固醇血症,已逐渐成为主要的致死原因。已有报道称,血浆胆固醇浓度增高导致脂肪、巨噬细胞和泡沫细胞沉积在血管壁上,此等沉积则导致斑块形成,并由此引发动脉粥样硬化(Ross,R.,Nature,362,801-809(1993))。降低血浆胆固醇浓度的方法之一是饮食料法,以降低胆固醇和脂质的摄入。另一种方法是通过抑制其中所涉及的酶来抑制胆固醇的吸收。
酰基CoA-胆固醇-O-酰基转移酶(ACAT)促进血液中胆固醇的酯化。泡沫细胞是在ACAT的作用下形成的,并包含大量的由低密度脂蛋白携带的胆固醇酯。泡沫细胞在动脉壁上的形成随ACAT的活性而增加,因此ACAT的抑制剂也可以是防止动脉粥样硬化的药剂。另外,已有人报道LDL-胆固醇的血浓可通过抑制ACAT的活性来降低(Witiak,D.T.和D.R.Feller(eds.),Anti-Lipidemic Drugs:Medicinal,Chemical and Biochemical Aspects,Elsevier,pp 159-195(1991))。
另一方面,由于过度摄入酒精或具有高脂质含量的食品、或者感染肝炎B或C病毒有可能发生肝功能的损坏,并有可能发展为肝炎、肝硬变或肝癌。具体而言,过量摄入含脂肪的食品和酒精导致脂肪肝,其中在肝组织中沉积了大量的脂质类物质,而且血清GOT(谷氨酸-草酰乙酸转氨酶)、GPT(谷氨酸-丙酮酸转氨酶)和γ-GTP(γ-谷氨酰基转肽酶)升高(T.Banciu等人,Med.Interne.,20,69-71(1982);以及A.Par等人,Acta.Med.Acad.Sci.Hung.,33,309-319(1976))。
已进行了许多努力来研制可以抑制ACAT活性的药物;其结果是已有几种从各种微生物的培养物中分离出的化合物。此等化合物的例子包括从Aspergillus fumigatus的培养物中分离出的pyripyropenes(S.Omura等人,J.Antibiotics,46,1168-1169(1993);以及从Pseudomonas sp.中分离出的Acaterin(S.Nagamura等人,J.Antibiotics,45,1216-1221(1992))。
另外,作为高胆固醇血症的治疗剂,Merck Co.,USA已研制并销售称为Lovastatin的HMG-CoA还原酶抑制剂。但是,已知该药物会诱发肝脏中肌酸激酶增加的副作用。
因此,仍有必要继续研制无毒性的ACAT和巨噬细胞-脂质复合物在动脉上皮上累积的抑制剂、以及肝病预防或治疗剂。
本发明的发明者努力由天然物质研制新型且强效的ACAT抑制剂、巨噬细胞-脂质复合物累积抑制剂以及肝病治疗剂,其结果是发现橙皮苷或橙皮素具有强效ACAT抑制活性、巨噬细胞-脂质复合物累积抑制活性、以及对肝病的预防或治疗活性。
橙皮苷(C28H34O15,M.W:610.55)和橙皮苷的配基——橙皮素(C16H14O6,M.W.:302.27)是存在于柠檬、葡萄柚、柑桔、枸橼和橙(Citrus sinensis)中的生物类黄酮(Horowitz,Gentili,Tetrahedron,19,773(1963))。
已有报道称,橙皮苷或橙皮素具有增强毛细管、降低渗透性、抗血小板聚集、抗炎、抗病毒以及降低血压和胆固醇的活性(Meyer,O.C.,Angiology,45,579-584(1994);Struckmann,J.R等人,Angiol.,45,419-428(1994);Matsubara,Y.等人,Japan Organic Synthesis Chem.AssociationJournal,52,318-327(1994,Mar.);Galati,E.M.等人,Famaco.,51(3),219-221(1996,Mar.);Monforte,M.T.等人,Farmaco.,50(9),595-599(1995,Sep.);JP 95-86929;JP 95-86930;Chung,M.I.等人,Chin.Pharm.J.(Taipei).,46,429-437(1994,Nov.);Galati,E.M.等人,Famaco.,40(11),709-712(1994,Nov.);以及Emim,J.A.等人,J.Pharm.Pharmacol.,46(2),118-122(1994))。
另外,橙皮苷已被用于预防和治疗脑贫血、视网膜出血和pelioma。
但是,目前尚没有人报道橙皮苷或橙皮素的ACAT抑制活性、巨噬细胞-脂质复合物累积抑制活性、以及对肝病的预防或治疗活性。
发明简述
因此,本发明的目的是提供橙皮苷或橙皮素抑制哺乳动物中ACAT活性的新用途。
本发明的另一个目的是提供橙皮苷或橙皮素抑制哺乳动物中巨噬细胞-脂质复合物在动脉内皮壁上累积的新用途。
本发明的再一个目的是提供橙皮苷或橙皮素预防或治疗哺乳动物中肝病的新用途。
附图简述
参考以下附图及描述,本发明的上述和其他目的及优点将更为显而易见,在附图中:
图1A、1B和1C显示了分别给药1%胆固醇、1%胆固醇加1mg/kgLovastatin、以及1%胆固醇加0.1%橙皮苷的兔动脉;以及
图2A、2B和2C代表分别给药1%胆固醇、1%胆固醇加1mg/kgLovastatin、以及1%胆固醇加0.1%橙皮苷的兔肝脏的显微特征。
发明详述
根据本发明的一个方面,其提供橙皮苷或橙皮素抑制哺乳动物中酰基CoA-胆固醇-O-酰基转移酶(ACAT)活性的新用途。
根据本发明的另一个方面,其提供橙皮苷或橙皮素抑制哺乳动物中巨噬细胞-脂质复合物在动脉内皮壁上累积的新用途。
根据本发明的再一个方面,其提供橙皮苷或橙皮素预防或治疗哺乳动物中肝病的新用途。
橙皮苷和橙皮素可从桔属植物的皮中提取,或者根据Zemplen,Bognar(Ber.,75,1043(1943))和Seka,Prosche(Monatsh.,69,284(1936))描述的方法来合成。另外,橙皮素可通过水解橙皮苷来制得。
橙皮苷或橙皮素在0.1mg/kg/天或更高的剂量时对ACAT活性和巨噬细胞-脂质复合物在动脉内皮壁上的累积具有抑制作用,而且对肝病具有预防和治疗作用,所述抑制作用随剂量而增加。
而且,尽管有强的效力,但橙皮苷或橙皮素在鼠实验中几乎没有表现出毒性或促有丝分裂性。更具体而言,当以100mg/kg的剂量给鼠口服给药时,橙皮苷或橙皮素没有产生毒性,对于50kg重的人来说,上述剂量相当于口服给药3-10g橙皮苷或橙皮素/kg体重。另外,橙皮苷和橙皮素对肝功能没有副作用。
本发明还提供用于抑制ACAT活性和巨噬细胞-脂质复合物在动脉内皮壁上累积、以及预防或治疗肝病的药物组合物,该组合物包括橙皮苷或橙皮素作为活性成分以及药物学上可接受的赋形剂、载体或稀释剂。
可根据任何常规方法来制备药物制剂。在制备制剂时,活性成分优选与载体混合或用载体稀释,或者包封在胶囊、小药囊或其他容器之形式的载体中。如果载体为稀释剂,其可为固体、半固体或液体物质,作为活性成分的载体、赋形剂或介质。因此,制剂可为片剂、丸剂、粉末、小药囊剂、甘香酒剂、混悬剂、乳剂、溶液、糖浆、气雾剂、软和硬明胶胶囊、无菌注射液、无菌包装的粉末等剂型。
合适的载体、赋形剂和稀释剂的例子是乳糖、葡萄糖、蔗糖、山梨醇、甘露醇、淀粉、阿拉伯树胶、藻酸盐、明胶、磷酸钙、硅酸钙、纤维素、甲基纤维素、微晶纤维素、聚乙烯吡咯烷酮、水、羟基苯甲酸甲酯、羟基苯甲酸丙酯、滑石粉、硬脂酸镁和矿物油。药物制剂可另外包括填料、抗附聚剂、润滑剂、润湿剂、调味剂、乳化剂、防腐剂等。本发明的组合物可用任何本领域已知的方法配制成在给药于哺乳动物后快速、持续或延迟释放活性成分的制剂。
本发明的药物制剂可通过各种途径给药,包括口服、透皮、皮下、静脉和肌肉给药。对于人,橙皮苷或橙皮素的典型日剂量是约0.1-100mg/kg体重,优选为3-10mg/kg,而且该剂量可以单剂量或多份剂量给药。
但应理解的是,实际给药的活性成分的量应根据各种相关因素来确定,所述因素包括待治疗的疾病、所选择的给药途径、每个患者的年龄、性别和体重、以及患者症状的严重程度;因此,上述剂量绝不是用于限制本发明的范围。
另外,橙皮苷或橙皮素可掺入在食品或饮料中,作为添加剂或食物增补剂,用于抑制ACAT活性、抑制巨噬细胞-脂质复合物在动脉内皮上的累积和/或预防或治疗肝病。食品或饮料可包括肉食;汁液如蔬菜汁(例如胡萝卜汁和番茄汁)和果汁(例如橙汁、葡萄汁、菠萝汁、苹果汁和香蕉汁);巧克力;小吃;糖果;意大利馅饼;由谷粉制成的食品,如面包、蛋糕、苏打饼干、曲奇饼干、饼干、面条等;口香糖;乳制品,如牛奶、乳酪、酸奶和冰淇淋;汤;肉汤;稀粥、番茄沙司和调味汁;茶;酒精饮料;碳酸饮料如开口可乐和百事可乐;维生素复合物;以及各种保健食品。
在此情况下,食品或饮料中的橙皮苷或橙皮素含量可在0.01-5%重量之间。具体而言,每1000ml根据本发明的饮料可包含200-10000mg的橙皮苷或橙皮素。
如上所述,橙皮苷或橙皮素可用作有效抑制ACAT活性、抑制巨噬细胞一脂质复合物在动脉内皮上累积、和/或预防或治疗肝病的非毒性药物。
以下实施例用于进一步阐明本发明,而不是限制其范围。
另外,以下固体混合物中之固体、液体中之液体、以及液体中之固体的百分比分别是以wt/wt、vol/vol和wt/vol计算,而且所有的反应都是在室温下进行,除非另有说明。实施例1:从桔皮中提取橙皮苷
在室温下干燥柑桔(Cheju Island,Korea)、枸橼(Jeollanamdo,Korea)以及橙、葡萄柚和柠檬(Califomia,CA,USA)的皮,然后粉碎成粒径为100-200μm的粉末。在500mg的上述各桔皮粉末中分别加入50ml的甲醇,然后在水浴中于50℃下提取6小时。冷却所得到的提取物,然后过滤,在滤液中添加甲醇至50ml的体积。
为证实如上制得的提取物中橙皮苷的含量,对0.5μl所述提取物进行高效液相色谱(HPLC)分析,其中使用Lichrosorb RP-8柱(5μm,4×250mm),所述色谱柱用37%甲醇预平衡并保持在30℃下。提取物用37%甲醇以1.0ml/min的流速洗脱。将橙皮苷(Sigma Chemical Co.,USA)溶解在甲醇中,使得最终浓度分别为0.1、0.2、0.3、0.4、和0.5mg/ml,由此制备标准溶液,然后在相同的条件下进行HPLC分析。在280nm下用UV-VIS分光光度计检测洗脱液,并通过比较桔皮提取物和标准溶液的HPLC曲线面积来计算橙皮苷的含量。各种桔皮提取物中的橙皮苷含量(%)见表I所示。
表I
实施例2:口服给药橙皮苷或橙皮素的毒性
橙皮苷(%) | |
橙 | 2.10 |
柠檬 | 1.40 |
柑桔 | 2.10 |
葡萄柚 | - |
枸橼 | 0.80 |
在22±1℃的温度、55±5%的湿度和光照周期12L/12D的条件下,饲养7-8周龄、无特定病原的ICR雌鼠(6只)和雄鼠(6只),雌鼠重量在25-29g,雄鼠重量在34-38g。将饲料(Cheiljedang Co.,鼠饲料)和水消毒,然后喂给小鼠。
将橙皮苷或橙皮素溶解在0.5%Tween 80中,至浓度为100mg/ml,然后将该溶液口服给药至小鼠,用量为0.2ml/20g小鼠体重。给药所述溶液后,按以下程序观察小鼠10天并记录副作用或死亡现象:给药后1、4、8和12小时,以后则每隔12小时观察。每天记录小鼠体重变化,以检查橙皮苷或橙皮素的作用。另外,在第10天时,将小鼠处死,并肉眼检查内部器官。
在第10天时所有小鼠都存活,而且1000mg/kg剂量的橙皮苷或橙皮素没有毒性。尸检结果是,小鼠没有形成任何病理非正常性,而且在10天的检查期间没有观察到体重减轻。因此,可得出以下结论:桔橙皮苷或橙皮素在口服给药于动物时没有毒性。实施例3:向动物给药橙皮苷或橙皮素
随机将体重为90-110g的30只4周龄Sprague-Dawley大鼠(Taihanlaboratory animal center,Korea)平均分成3个饮食组。三个组的大鼠分别用三种不同的高胆固醇食物喂养,即包含1%胆固醇的AIN-76实验室动物饲料(ICN Biochemicals,Cleveland,OH,USA)(对照组),以及1%胆固醇加0.1%橙皮苷或橙皮素。三个组所用饲料的成分见下表II。
表II
饲料成分 | 对照组 | 橙皮苷组 | 橙皮素组 |
酪蛋白 | 20 | 20 | 20 |
D,L-蛋氨酸 | 0.3 | 0.3 | 0.3 |
玉米淀粉 | 15 | 15 | 15 |
蔗糖 | 49 | 48.9 | 48.9 |
纤维素粉末* | 5 | 5 | 5 |
矿物质混合物* | 3.5 | 3.5 | 3.5 |
维生素混合物* | 1 | 1 | 1 |
重酒石酸胆碱 | 0.2 | 0.2 | 0.2 |
玉米油 | 5 | 5 | 5 |
胆固醇 | 1 | 1 | 1 |
橙皮苷 | 0.1 | ||
橙皮素 | - | - | 0.1 |
总计 | 100 | 100 | 100 |
*:从TEKLAD Premier Co.(Madison,WI,U.S.A.)购得
无限制地用具体饲料和水喂养大鼠共6周,每日记录摄取量,然后每7天称重,并分析记录数据。所有大鼠都显示正常的生长速度,而且三个组之间在食物摄取量和体重增加方面没有显著差异。实施例4:血浆中总胆固醇、HDL-胆固醇和中性脂质含量的测定
以下测定向大鼠给药橙皮苷或橙皮素对血浆胆固醇和中性脂质含量的影响。
从以上三个组的大鼠中采取血样,并用包含葡萄糖硫酸酯的HDL-胆固醇试剂(Sigma Chemical Co.,Cat.No.352-3)从中分离血浆HDL成分。用Sigma Diagnostic Kit Cat.No.352-100(Sigma Chemical Co.,USA)测定总胆固醇和HDL-胆固醇浓度(Allain et al.,Clin.Chem.,20,470-475(1974))。用Sigma Diagnostic Kit Cat.No.339-50(SigmaChemical Co.,USA)测定中性脂质浓度(Bucolo,G.和David,H.,Clin.Chem.,19,476-482(1973))。结果见表III,其中,与对照组大鼠相比,橙皮苷和橙皮素饲养组中大鼠的总血浆胆固醇浓度分别下降32%和18%。
表 III
组脂质浓度 | 对照组 | 橙皮苷组 | 橙皮素组 |
总胆固醇(mg/dl) | 147.8±34.8 | 131.6±29.7 | 125.1±15.6 |
HDL-胆固醇(mg/dl) | 22.2 | 18.7 | 25.7 |
HDL-胆固醇/总胆固醇(%) | 15.7±5.3 | 15±4.9 | 20±5.6 |
TG(mg/dl) | 99.2±18.9 | 92.7±20.5 | 114.6±18.8 |
TG:甘油三酯实施例5:橙皮苷和橙皮素在ACAT抑制中的活性(步骤1)制备微粒体
为确定用橙皮苷或橙皮素饲养大鼠对ACAT活性的作用,从肝组织中制备微粒体作为酶源。
首先,将实施例3中的三组大鼠断头处死,并取出肝脏。分别将1g肝脏在5ml匀浆介质(50mM KH2PO4(pH 7.4),0.1 MEDTA,2mMβ-巯基乙醇)中均化。在4℃、3000×g下离心所述匀浆10分钟,然后在40℃、15000×g下离心所得到的上清液15分钟,由此得到上清液。将上清液放入超离心管(Beckman)中,并在100000×g、4℃下离心1小时,以得到微粒体沉淀物,然后将该沉淀物悬浮在3ml的匀浆介质中,并在4℃、100000×g下离心1小时。将由此得到的沉淀物悬浮在1ml匀浆介质中。用Lowry法测定所得悬浮液中蛋白质的含量,然后调节至4-8mg/ml。将所得悬浮液储存在深冷冻机(Bioffeezer,Forma Scientific Inc.)中。(步骤2)ACAT实验
在丙酮中将6.67μl的1mg/ml胆固醇丙酮溶液与6μl的10%TritonWR-1339(Sigma Co.)混合,然后通过使用氮气进行蒸发来除去丙酮。在所得的混合物中添加蒸馏水,其量是将胆固醇的浓度调节为30mg/ml。
在10μl得到的胆固醇水溶液中添加10μl的1M磷酸二氢钾(pH7.4)、5μl的0.6mM牛血清白蛋白(BSA)、10μl的步骤1中制得的微粒体溶液和55μl的蒸馏水(总共90μl)。在水浴中于37℃下预温育该混合物30分钟。
将10μl(1-14C)油酰-CoA溶液(0.05μCi,最终浓度10μM)添加至经预温育的混合物中,在水浴中于37℃下温育所得的混合物30分钟。在该混合物中添加500μl的异丙醇∶庚烷混合物(4∶1v/v)、300μl的庚烷和200μl的0.1M磷酸二氢钾(pH 7.4),然后使用vortex剧烈搅拌混合物,并在室温下静置2分钟。
将200μl所得的上清液放入闪烁瓶中,并在其中添加4ml的闪烁液(Lumac)。用1450 Microbeta液体闪烁计数器(Wallacoy,Finland)对混合物进行放射活性分析。以每mg蛋白每分钟合成的胆固醇油酸酯的pmol数(pmoles/min/mg蛋白)计算ACAT活性。结果见表IV。
表IV
组 | ACAT活性(pmol/min/mg蛋白) | 对ACAT活性的抑制百分数 |
对照组 | 806.2±105.2 | 0 |
0.1%橙皮苷组 | 851.2±86.0 | 19.2 |
0.1%橙皮素组 | 616.4±60.5 | 23.5 |
从表IV的结果可以看出,橙皮苷和橙皮素组大鼠中ACAT活性分别低于对照组19.2%和23.5%。实施例6:在橙皮苷和橙皮素饲养动物中对由巨噬细胞-脂质复合物导致的斑块形成的抑制作用(步骤1)向动物给药橙皮苷和橙皮素
在20±2℃的温度、55±5%的相对湿度和光照周期12L/12D的条件下,饲养24只重量分别为2.5-2.6kg的3月龄新西兰白兔(YeonamHorticulture and Animal Husbandry College,Korea)。将上述兔子分为4个组,然后向4个组的兔子饲养4种不同的饲料,即分别是:包含1%胆固醇的RC4饲料(Oriental Yeast Co.,Japan)(对照组);1%胆固醇加1mg/kg Lovastatin(Merck,USA)(对比组);1%胆固醇加0.1%橙皮苷;以及1%胆固醇加0.1%橙皮素。RC4饲料包含7.6%水分、22.8%粗蛋白、2.8%粗脂肪、8.8%粗灰、14.4%粗纤维素和43.6%可溶性无氮物质。兔子饲养6周,并可自由摄取饲料和水。(步骤2)分析动物动脉中的脂肪条纹
将步骤1中饲养的兔子杀死,然后切开胸部。由主动脉阀上1cm的部位开始向下切除长度约为5cm的主动脉,然后除去主动脉周围的脂肪。沿纵轴中间切开主动脉,并钉在板上。对湿的动脉进行照相,然后如下根据Esper,E.等人的方法(J.Lab.Clin.Med.,121,103-110(1993))对脂肪条纹进行染色。
用无水丙二醇在2分钟内洗涤一部分经切可的主动脉3次,然后用Oil Red O(ORO,Sigman Co.)的丙二醇饱和溶液染色30分钟。之后,用85%丙二醇溶液在3分钟内洗涤主动脉2次,以除去残留的染色溶液,再用生理盐水洗涤。对主动脉进行照相,并跟踪照相。用图象分析仪(LEICA,Q-600,Germany)测定染色区域(脂肪条纹区域)的面积,并计算与总主动脉面积的比例(%)。
另一方面,根据苏木精-曙红(H&E)和Masson′s三色染色法对主动脉的其他部分进行染色,然后在显微镜下观察,以证实巨噬细胞-脂质复合物是否累积在内膜、管腔中部、弹性层和中层。
另外,从兔子中采取血样,并根据与实施例4相同的方法测定总胆固醇和甘油三酯。
结果见表V所示。
表V
*M-L复合物:巨噬细胞-脂质复合物
饲料组 | 总胆固醇(mg/dl) | 甘油三酯(mg/dl) | M-L*复合物面积(%) |
对照 | 1143 | 56 | 35 |
1mg/kg Lovastatin组 | 1210 | 66 | 5 |
0.1%橙皮苷组 | 1130 | 40 | 13.5 |
0.1%橙皮素组 | 1150 | 41 | 13 |
由表V可以看出,与对照组相比,1mg/ml Lovastatin、0.1%橙皮苷和0.1%橙皮素组中累积在动脉内皮上的巨噬细胞-脂质复合物面积显著降低。因此,证实橙皮苷和橙皮素可抑制巨噬细胞-脂质复合物在动脉内皮上的累积。具体而言,明显可以看出,在高于1100mg/dl的胆固醇血液浓度时橙皮苷和橙皮素对巨噬细胞-脂质复合物的累积具有抑制活性,所述胆固醇浓度大大高于正常兔子的浓度,即、约50mg/dl。该结果提示有新的机制防止动脉粥样硬化的开始,这与HMG-CoA还原酶抑制剂阻断胆固醇合成、ACAT抑制剂阻断胆固醇吸收、或者CETP抑制剂阻断胆固醇转移不同。
图1A、1B和1C显示了分别给药1%胆固醇(对照组);1%胆固醇加1mg/kg Lovastatin(对比组);和1%胆固醇加0.1%橙皮苷的兔子的动脉。如图1A、1B和1C所示,在给药1%胆固醇的兔子的动脉内皮上观察到厚层的巨噬细胞-脂质复合物,而在分别给药1%胆固醇加1mg/kg Lovastatin、和1%胆固醇加0.1%橙皮苷的兔子的动脉内皮上几乎没有或者仅观察到较薄层的巨噬细胞-脂质复合物。
因此,可以得出以下结论:橙皮苷和橙皮素可强烈地抑制巨噬细胞-脂质复合物在动脉内皮上的累积。实施例7:橙皮苷对肝病的预防(步骤1)向鼠给药橙皮苷
随机将20只重量为约90-110g的Sprague-Dawley大鼠(TaihanLaboratory Animal Center,Korea)平均分为二个饲料组。这2个组的大鼠分别喂以2种不同的高胆固醇饲料,即、包含1%胆固醇的AIN-76实验室动物饲料(ICN Biochemicals,Clevand,OH,USA)(对照组);以及1%胆固醇加0.02%橙皮苷。2个组的饲料的组成见表VI所示。
表VI
饲料组成分 | 对照组 | 0.02%橙皮苷组 |
酪蛋白 | 20 | 20 |
D,L-蛋氨酸 | 0.3 | 0.3 |
玉米淀粉 | 15 | 15 |
蔗糖 | 39 | 38.98 |
纤维素粉末* | 5 | 5 |
矿物质混合物* | 3.5 | 3.5 |
维生素混合物* | 1 | 1 |
重酒石酸胆碱 | 0.2 | 0.2 |
脂肪 | 15 | 15 |
胆固醇 | 1 | 1 |
橙皮苷 | - | 0.02 |
总计 | 100 | 100 |
*:购自于TEKLAD Premier Co.(Madison,WI,USA)
无限制地用具体饲料和水喂养大鼠共6周,每日记录摄取量,然后每7天称重,并分析记录数据。所有大鼠都显示正常的生长速度,而且二个组之间在食物摄取量和体重增加方面没有显著差异。(步骤2)测定血清GOT和GPT浓度
如下测定给药橙皮苷对鼠肝功能的作用。
从2个组的鼠中采取血液,然后根据Reitman和Frankel的方法(Reitman,S.和J.S.Frankel,Am.J.Clin.Pathol.,28,56(1956))测定血清GOT(谷氨酸-草酰乙酸转氨酶)和GPT(谷氨酸-丙酮酸转氨酶)。GOT和GPT是在肝脏和心脏中合成的,并在这些器官被损坏时释放在血液中。因此,GOT和GPT是肝功能的代表性指标,而高血清GOT和GPT浓度代表肝脏受到严重损伤。
结果显示,橙皮苷组的GOT和GPT浓度较对照组的分别低约30%和10%。(步骤3)使用兔子的实验
重复步骤1中的相同步骤,但使用30只重量分别为约2.5-2.6kg的3月龄新西兰白兔(Yeonam Horticulture and Animal Husbandry College,Korea)代替鼠,然后用3种不同的饲料分别喂养所述兔子,即、包含1%胆固醇的RC4饲料(对照组);1%胆固醇加1mg/kg Lovastatin(对比组);以及1%胆固醇加0.1%橙皮苷。
之后,从兔子中分离肝脏,并如下所述进行组织病理学观察。
肌肉注射氯胺酮(75mg/kg)麻醉兔子,然后切开腹部。肉眼观察肝脏硬化的颜色和程度,并将从兔中分离的肝脏用10%中性缓冲福尔马林固定24小时以上。用水充分洗涤经固定的肝脏,分步用70%、80%、90%和100%乙醇脱水,然后嵌在石蜡中。用切片机将嵌入的肝脏切成4μm的厚度,并用苏木精和曙红染色。用二甲苯使经染色的肝脏样品呈透明状,用permount固定,然后用显微镜观察,以证实损伤的存在。
图2A、2B和2C分别代表了给药1%胆固醇(对照组)、1%胆固醇加1mg/kg Lovastatin(对比组)、和1%胆固醇加0.1%橙皮苷的兔子肝脏的显微特征。如图2A和2B所示,对照组和对比组的肝细胞为不规则地排列并增大,而且其中沉积大量的脂肪。相反地,如图2C所示,橙皮苷组的肝细胞为正常,而且没有观察到脂肪的沉积。该结果表明,橙皮苷强烈地抑制脂肪肝的发生,而且对肝细胞没有毒副作用。(步骤4)使用人的实验
以10mg/kg的剂量向一位55岁的男人给药橙皮苷共68天,并分别在开始给药之前(第0天)以及给药后的45和68天(第45和68天)时测定GOT、GPT和γGTP。其结果是,与第0天时的相比,第45和68天时的血清GOT浓度分别降低17%。与第0天时的相比,第45和68天时的血清GPT浓度分别降低15%和19%。而且,与第0天时的相比,第45和68天时的血清γGTP浓度分别降低25%和51%。令人惊奇的是,与第0天时的相比,血清γGTP浓度在第68天时降低50%以上。该结果表明,橙皮苷或橙皮素对肝病如肝炎、脂肪肝和酒精性脂肪肝具有强效的肝保护活性。
另一方面,以6mg/kg的每日剂量向一位56岁的男性口服给药橙皮苷共30天,该男性每天习惯性地饮用100cc的酒精饮料,然后在给药之前(第0天)和给药之后30天(第30天)测定血清γGTP浓度。其结果是,第0天时的初始血清γGTP浓度为129IU/1,而第30天时的浓度降低至69TU/1,达到了正常范围。该结果证实橙皮苷或橙皮素对预防酒精性脂肪肝和肝硬变具有高活性。实施例9:包含橙皮苷或橙皮素的食品
如下制造包含橙皮苷或橙皮素的食品。
(1)制造番茄沙司和调味汁
将橙皮苷或橙皮素添加至番茄沙司或调味汁中,其量为0.01-5wt%,以得到更有益于健康的番茄沙司或调味汁。
(2)制造小麦粉食品
将橙皮苷或橙皮素添加至小麦粉食品中,其量为0.01-5wt%,并使用该混合物制造面包、蛋糕、曲奇饼干、苏打饼干、和面条,以得到更有益于健康的食品。
(3)制造汤和肉汁
将橙皮苷或橙皮素添加至汤和肉汁中,其量为0.01-5wt%,以得到更有益于健康的汤和肉汁。
(4)制造牛肉末
将橙皮苷或橙皮素添加至牛肉末中,其量为0.01-5wt%,以得到更有益于健康的牛肉末。
(5)制造乳制品
将橙皮苷或橙皮素添加至牛奶中,其量为0.01-5wt%,然后使用该牛奶制造各种乳制品如黄油和冰淇淋。
但是,在制造乳酪时,将橙皮苷或橙皮素添加至凝聚乳蛋白中;而在制造酸奶时,则将橙皮苷或橙皮素添加至发酵后得到的凝聚乳蛋白中。实施例10:包含橙皮苷或橙皮素的饮料
(1)制造蔬菜汁
将200-10000mg橙皮苷或橙皮素添加至1000ml番茄或胡萝卜汁中,以制得更有益于健康的蔬菜汁。
(2)制造果汁
将200-10000mg橙皮苷或橙皮素添加至1000ml苹果或葡萄汁中,以制得更有益于健康的果汁。
(3)制造碳酸饮料
将200-10000mg橙皮苷或橙皮素添加至1000ml可口可乐或百事可乐中,以制得更有益于健康的碳酸饮料。
虽然已参考上述具体实施方案对本发明进行了描述,但应认识到,本领域技术人员在本发明的范围内还可进行各种改进和变化,而本发明的范围为以下权利要求书所限定。
Claims (8)
1、橙皮苷或橙皮素在制备用于预防或治疗哺乳动物之脂肪肝的组合物中的应用。
2、如权利要求1所述的应用,其中,所述哺乳动物是人。
3、如权利要求1所述应用,其中,所述组合物选自于以下组中:药物组合物、食品组合物和饮料组合物。
4、如权利要求3所述的应用,其中,在食品组合物中包含的橙皮苷或橙皮素的含量为0.01-5重量%。
5、如权利要求3所述的应用,其中,所述食品组合物是肉食、巧克力、小吃、糖果、意大利馅饼、由谷粉制成的食品、口香糖、乳制品、汤、肉汤、稀粥、番茄沙司、调味汁、维生素复合物、或保健食品。
6、如权利要求5所述的应用,其中,所述由谷粉制成的食品是面包、蛋糕、苏打饼干、曲奇饼干、饼干、或面条。
7、如权利要求3所述的应用,其中,所述饮料组合物是乳制品、蔬菜汁、果汁、茶、酒精饮料或碳酸饮料
8、如权利要求3所述的应用,其中,在饮料组合物中的橙皮苷或橙皮素含量为每1000ml饮料200-10000mg。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019970055578A KR19990034089A (ko) | 1997-10-28 | 1997-10-28 | 헤스페리딘또는헤스페레틴을포함하는아실코에이:콜레스테롤-오르토-아실트랜스퍼레이즈 저해제조성물 |
KR1997/55578 | 1997-10-28 | ||
KR1998/10888 | 1998-03-28 | ||
KR1019980010888A KR19990076178A (ko) | 1998-03-28 | 1998-03-28 | 헤스페리딘을 포함하는 간 질환의 예방 및 치료용 조성물 |
KR1019980012411A KR19990079683A (ko) | 1998-04-08 | 1998-04-08 | 감귤류의 과피 분말 또는 과피 추출물을 포함하는 기능성 건강식품 |
KR1998/12411 | 1998-04-08 | ||
KR1998/13283 | 1998-04-14 | ||
KR1019980013283A KR19990080214A (ko) | 1998-04-14 | 1998-04-14 | 감귤류의 과피 추출물을 포함하는 건강개선용 기능성 음료 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1278170A CN1278170A (zh) | 2000-12-27 |
CN1124133C true CN1124133C (zh) | 2003-10-15 |
Family
ID=27483239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98810701A Expired - Fee Related CN1124133C (zh) | 1997-10-28 | 1998-10-20 | 橙皮苷和橙皮素作为肝病的预防或治疗剂的应用 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1063988A1 (zh) |
JP (1) | JP2001520993A (zh) |
CN (1) | CN1124133C (zh) |
CA (1) | CA2307890A1 (zh) |
WO (1) | WO1999021549A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI715172B (zh) * | 2019-08-28 | 2021-01-01 | 健茂生物科技股份有限公司 | 具有抑制體脂肪形成之組合物 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020006953A1 (en) * | 1999-11-05 | 2002-01-17 | Carla R. McGill | Modification of cholesterol concentrations with citus phytochemicals |
FR2841472B1 (fr) | 2002-06-28 | 2006-02-24 | Agronomique Inst Nat Rech | Composition nutritionnelle ou therapeutique contenant le compose hesperidine ou l'un de ses derives |
AU2005264590B2 (en) * | 2004-07-23 | 2012-03-01 | Suntory Holdings Limited | Alcohol-dipped material, food or drink using the same and method of production thereof |
KR20070095338A (ko) | 2004-12-24 | 2007-09-28 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 간기능 개선제 |
EP2368442B1 (en) | 2005-07-27 | 2014-12-17 | Symrise AG | Use of hesperetin for enhancing the sweet taste |
CA2640060A1 (en) | 2006-01-23 | 2007-07-26 | Suntory Limited | Food or drink and method of production thereof |
JP2007112806A (ja) * | 2006-11-27 | 2007-05-10 | Kao Corp | 体脂肪燃焼促進剤 |
JP2009007256A (ja) * | 2007-06-26 | 2009-01-15 | Kao Corp | Nadh/nadphオキシダーゼ抑制剤 |
CN104688756A (zh) * | 2013-12-09 | 2015-06-10 | 中国药科大学 | 一种药物组合物及其在制备治疗酒精性肝损伤药物中的应用 |
CN114832041A (zh) * | 2021-02-01 | 2022-08-02 | 健茂生物科技股份有限公司 | 具有护肝效果的组合物及其制备方法 |
CN114832007A (zh) * | 2021-02-01 | 2022-08-02 | 健茂生物科技股份有限公司 | 降低胆固醇的组合物及其制备方法 |
CN115607538A (zh) * | 2022-09-26 | 2023-01-17 | 浙江工商大学 | 橙皮素在制备抑制和/或治疗小麦过敏的药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4150038A (en) * | 1977-05-16 | 1979-04-17 | Dynapol | Conversion of hesperidin into hesperetin |
JPH08283154A (ja) * | 1995-04-12 | 1996-10-29 | Nippon Shinyaku Co Ltd | 脂質代謝改善剤 |
JPH08280358A (ja) * | 1995-04-12 | 1996-10-29 | Nippon Shinyaku Co Ltd | 脂質代謝改善に有効な食品及び製法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54154569A (en) * | 1978-05-20 | 1979-12-05 | Lotte Co Ltd | Chewing gum for sports |
WO1989005141A1 (en) * | 1987-12-10 | 1989-06-15 | Tsumura Juntendo, Inc. | Anti-retroviral drug |
MC2041A1 (fr) * | 1988-06-24 | 1990-05-30 | Johannes Cornelius Str Andries | Agents anti-atherogenic |
JPH04295428A (ja) * | 1991-03-22 | 1992-10-20 | Dai Ichi Seiyaku Co Ltd | 抗アレルギー剤 |
JPH08509224A (ja) * | 1993-04-20 | 1996-10-01 | ザ、プロクター、エンド、ギャンブル、カンパニー | 皮脂抑制および▲ざ▼瘡治療のためのヘスペレチンの使用方法 |
JPH0725761A (ja) * | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
-
1998
- 1998-10-20 JP JP2000517707A patent/JP2001520993A/ja active Pending
- 1998-10-20 WO PCT/KR1998/000324 patent/WO1999021549A1/en not_active Application Discontinuation
- 1998-10-20 CA CA002307890A patent/CA2307890A1/en not_active Abandoned
- 1998-10-20 CN CN98810701A patent/CN1124133C/zh not_active Expired - Fee Related
- 1998-10-20 EP EP98951777A patent/EP1063988A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4150038A (en) * | 1977-05-16 | 1979-04-17 | Dynapol | Conversion of hesperidin into hesperetin |
JPH08283154A (ja) * | 1995-04-12 | 1996-10-29 | Nippon Shinyaku Co Ltd | 脂質代謝改善剤 |
JPH08280358A (ja) * | 1995-04-12 | 1996-10-29 | Nippon Shinyaku Co Ltd | 脂質代謝改善に有効な食品及び製法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI715172B (zh) * | 2019-08-28 | 2021-01-01 | 健茂生物科技股份有限公司 | 具有抑制體脂肪形成之組合物 |
Also Published As
Publication number | Publication date |
---|---|
WO1999021549A1 (en) | 1999-05-06 |
JP2001520993A (ja) | 2001-11-06 |
CA2307890A1 (en) | 1999-05-06 |
CN1278170A (zh) | 2000-12-27 |
EP1063988A1 (en) | 2001-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1124134C (zh) | 柚苷和柚苷配基作为肝病的预防或治疗剂的应用 | |
CN1278182A (zh) | 作为酰基CoA-胆固醇-O-酰基转移酶抑制剂、巨噬细胞-脂质复合物在动脉壁上累积的抑制剂,以及肝病的预防或治疗剂的桔皮提取物 | |
CN1317972A (zh) | 用于预防或治疗与血脂水平升高相关的疾病的含有芸香苷和五羟黄酮的组合物 | |
US8895079B2 (en) | Combinations of botanical extracts for promoting cardiovascular health | |
EP2799083B1 (en) | Muscle atrophy inhibitor | |
CN1124133C (zh) | 橙皮苷和橙皮素作为肝病的预防或治疗剂的应用 | |
JP2002524477A (ja) | 高血中脂質濃度に因る疾患の予防または治療のための、天然フェノール性化合物を含む組成物 | |
KR101640258B1 (ko) | 적포도 추출물, 녹차 추출물, 대두 추출물 및 l-카르니틴을 유효성분으로 함유하는 항비만 조성물 | |
KR101464337B1 (ko) | 고욤나무 추출물을 유효성분으로 함유하는 항비만용 조성물 | |
TWI239245B (en) | Medical composition for oral administration or intravenous administration for a disease requiring enhancement of nerve growth factor production for treatment or prevention | |
EP1161944B1 (en) | Drugs, foods and oral compositions containing stilbene-type compounds | |
CN1317961A (zh) | 用于预防或治疗与血脂水平升高相关的疾病的含有肉桂酸衍生物的组合物 | |
US9655878B2 (en) | Composition comprising coumestrol or a bean extract containing coumestrol | |
JP2004091464A (ja) | 肥満抑制剤 | |
JPWO2005074961A1 (ja) | 体脂肪調整剤 | |
CN1791400A (zh) | 用于降低体内脂质的组合物 | |
KR101820096B1 (ko) | 콩 발아배아 추출물을 포함하는 대사성 질환의 예방 또는 치료용 약학 조성물 | |
US20070298136A1 (en) | Cholesterol regulating agent | |
JP2001322935A (ja) | 神経細胞賦活剤およびその利用 | |
JP2009114158A (ja) | 血糖値上昇抑制剤 | |
KR101340040B1 (ko) | 맥아 추출물을 유효성분으로 포함하는 비만 및 대사성 질환 예방 및 치료용 조성물 | |
US20090292012A1 (en) | Therapeutic Agent | |
JP2009167154A (ja) | 血糖値上昇抑制剤 | |
KR20010015495A (ko) | 루틴 및 쿼세틴을 포함하는 고지혈증, 동맥경화증 및 간질환의 예방 및 치료용 조성물 | |
JP2009167152A (ja) | 血糖値上昇抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |